By analyzing tissue and blood samples from PC patients, the findings suggest that CD39 and CD73 could serve as valuable biomarkers for prostate cancer, aiding in diagnosis and treatment strategies (61). This evidence concerns the gene ENTPD1 and prostate cancer.